164 related articles for article (PubMed ID: 10335764)
1. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I.
Crouse JR; Frohlich J; Ose L; Mercuri M; Tobert JA
Am J Cardiol; 1999 May; 83(10):1476-7, A7. PubMed ID: 10335764
[TBL] [Abstract][Full Text] [Related]
2. Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies.
Wierzbicki AS; Mikhailidis DP
Int J Cardiol; 2002 Jul; 84(1):53-7. PubMed ID: 12104065
[TBL] [Abstract][Full Text] [Related]
3. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
[TBL] [Abstract][Full Text] [Related]
4. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
5. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Jones P; Kafonek S; Laurora I; Hunninghake D
Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia.
Recto CS; Acosta S; Dobs A
Clin Cardiol; 2000 Sep; 23(9):682-8. PubMed ID: 11016019
[TBL] [Abstract][Full Text] [Related]
7. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
Davidson MH; Ose L; Frohlich J; Scott RS; Dujovne CA; Escobar ID; Bertolami MC; Cihon F; Maccubbin DL; Mercuri M
Clin Cardiol; 2003 Nov; 26(11):509-14. PubMed ID: 14640465
[TBL] [Abstract][Full Text] [Related]
9. High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
Wierzbicki AS; Lumb PJ; Semra YK; Crook MA
QJM; 1998 Apr; 91(4):291-4. PubMed ID: 9666952
[TBL] [Abstract][Full Text] [Related]
10. Comparison of atorvastatin alone versus simvastatin +/- cholestyramine in the management of severe primary hypercholesterolaemia (the six cities study).
Simons LA
Aust N Z J Med; 1998 Jun; 28(3):327-33. PubMed ID: 9673745
[TBL] [Abstract][Full Text] [Related]
11. Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia.
Branchi A; Fiorenza AM; Torri A; Muzio F; Berra C; Colombo E; Dalla Valle E; Rovellini A; Sommariva D
Clin Ther; 2001 Jun; 23(6):851-7. PubMed ID: 11440285
[TBL] [Abstract][Full Text] [Related]
12. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
[TBL] [Abstract][Full Text] [Related]
13. High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia.
Wierzbicki AS; Lumb PJ; Chik G; Crook MA
Am J Cardiol; 2000 Sep; 86(5):547-9, A9. PubMed ID: 11009276
[TBL] [Abstract][Full Text] [Related]
14. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
15. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.
Insull W; Ghali JK; Hassman DR; Y As JW; Gandhi SK; Miller E;
Mayo Clin Proc; 2007 May; 82(5):543-50. PubMed ID: 17493418
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.
Jones PH; McKenney JM; Karalis DG; Downey J
Am Heart J; 2005 Jan; 149(1):e1. PubMed ID: 15660024
[TBL] [Abstract][Full Text] [Related]
17. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
Karalis DG; Ishisaka DY; Luo D; Ntanios F; Wun CC
Am J Cardiol; 2007 Aug; 100(3):445-9. PubMed ID: 17659926
[TBL] [Abstract][Full Text] [Related]
18. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
[TBL] [Abstract][Full Text] [Related]
19. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical decrease in serum high-density lipoprotein cholesterol and lipid-lowering drugs.
Crook MA
Ann Clin Biochem; 2011 Jan; 48(Pt 1):3-4. PubMed ID: 21273636
[No Abstract] [Full Text] [Related]
[Next] [New Search]
